Correlation of placenta previa and liver enzyme abnormalities with recurrent pregnancy loss in women

Recurrent pregnancy loss (RPL) affects 1% to 5% of women of reproductive age, Even after thoroughly evaluating recurrent pregnancy loss etiology and risk factors about 75% of cases remaining unexplained. While the roles of hormonal imbalances, infections, and anatomical anomalies have been investigated, liver enzyme dysregulation and placenta previa remain poorly understood in their potential contributions to RPL. This study investigates these associations to improve outcomes for women with RPL. This study investigates the correlation between placenta previa, liver enzyme alterations, and recurrent pregnancy loss in a cohort of women from Telafar City. In a cross-sectional, case-control study, 80 non-pregnant women with a history of RPL were compared with 60 healthy controls without a history of miscarriage. Placental status was clinically assessed, and liver function was evaluated by measuring serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and gamma-glutamyltransferase (GGT). The study found that 79% of women with RPL exhibited placenta previa, a condition not observed in the control group. Additionally, women with RPL demonstrated significantly elevated levels of AST (19.7750 ± 5.5 U/L), ALT (17.7 ± 7.7 U/L), and GGT (21.9375 ± 9.5 U/L) compared to controls, while ALP levels were notably reduced in the RPL group (95.5250±35.5U/L vs. 124.650±19.6U/L). According to these results, placenta previa and liver enzyme dysregulation may play a role in the pathophysiology of recurrent pregnancy loss. In addition to the importance of being aware of the status of the placenta and liver function to avoid another miscarriage.